Core Viewpoint - Meizhong Jiahe Medical Technology Development Group Co., Ltd. has demonstrated significant revenue growth and improved profitability in the first half of 2025, despite a general decline in the industry [1][2]. Group 1: Financial Performance - As of June 30, 2025, the company achieved revenue of 201 million yuan, with hospital business revenue of 153 million yuan, reflecting a year-on-year growth of 11.2% [1]. - The company reported a gross profit of 400,000 yuan, marking a significant turnaround from a loss in the same period last year [1]. - The proportion of basic medical insurance fund payments decreased to 25% in 2025 from 41% in 2024 [1]. Group 2: Business Operations - The hospital business accounted for approximately 76.3% of total revenue, indicating its critical role in the company's financial structure [1]. - The opening of the first proton therapy center in South China at Guangzhou Taihe Hospital has led to a noticeable improvement in hospital business profitability, with gross margin rising from -22.1% to 0.4% [1]. - The proton therapy center has seen continuous growth in patient consultations and treatments since its launch, positioning it as a leading facility in the region [2]. Group 3: Technological Advancements - The company launched a self-developed large language model focused on proton therapy in May 2025, enhancing its technological capabilities in this field [2]. - This model integrates a vast array of high-quality treatment data and literature, which is expected to improve operational efficiency and extend its influence in the industry [2]. - Meizhong Jiahe has established strategic partnerships with renowned institutions like Mayo Clinic and MD Anderson Cancer Center, further solidifying its competitive edge in high-end medical services [3]. Group 4: Future Growth Potential - The ongoing development of proton therapy services, rapid advancements in AI models, and the upcoming openings of additional hospitals are anticipated to unlock significant growth potential for the company [3]. - The company is well-positioned to leverage its comprehensive advantages in medical equipment, treatment drugs, and patient care to enhance its market position [3].
美中嘉和2025年中期业绩：质子治疗与AI双轮驱动 毛利润扭亏为盈